The proteomics R&D department is fully equipped to identify, characterize, clone and produce novel protein biomarkers useful for the development and commercialization of diagnostic reagents and tests. The team has strong experience in immunoproteomics, antibodies generation, ELISA assay development and multiplex assay development on the Luminex® platforms.

Current multiplex product development, for simultaneous assessment of various analytes, involves full in-house optimization of reagents, beads, immunoassay protocols (antigen coating, specific multi-analyte detection), and statistical analysis tools (development of algorithms for mono or multiparametric data interpretation) for the Luminex’ 100/200 and MagPix platforms. Our experience in immunodiagnostics also allows for the development of the right test on the most suitable commercial platform.

Example: development of our proprietary BJI InoPlex™ kit

-Collection of positive and negative sera from patients with or without articular prosthesis infections

-Immunoproteomic identification of bacterial candidate antigens involved in prosthesis infections

-Cloning, purification and validation by rapid ELISA screening of the selected candidate antigens

-Development of the test on the Luminex® platform:

. Antigen bead coating optimization
. Immunoassay procedure implementation for specific multi analyte (multiplex) detection
. Algorithm of interpretation (combines intensity and distribution of response for each antigen)

The proteomics R&D department also participates to several consortiums:
Within the TEDAC Consortium: development of a test to monitor the direct effect of ERYTECH’s drug activity by measuring the depletion of amino acids.
Within the recently funded PROTHEVIH Consortium: development of a companion test and a diagnostic test centered on the measurement of the level of anti-3S antibodies in HIV-1 infected patients and those treated with InnaVirVax’s therapeutic vaccine